Huntington National Bank boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 37.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,903 shares of the medical research company’s stock after buying an additional 51,021 shares during the period. Huntington National Bank’s holdings in Amgen were worth $28,590,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Bowling Portfolio Management LLC boosted its position in shares of Amgen by 46.5% in the first quarter. Bowling Portfolio Management LLC now owns 61,778 shares of the medical research company’s stock worth $9,262,000 after buying an additional 19,600 shares in the last quarter. Northern Oak Wealth Management Inc. boosted its position in shares of Amgen by 8.5% in the first quarter. Northern Oak Wealth Management Inc. now owns 33,774 shares of the medical research company’s stock worth $5,064,000 after buying an additional 2,640 shares in the last quarter. Compton Capital Management Inc. RI boosted its position in shares of Amgen by 1.5% in the first quarter. Compton Capital Management Inc. RI now owns 6,060 shares of the medical research company’s stock worth $909,000 after buying an additional 90 shares in the last quarter. Badgley Phelps & Bell Inc. boosted its position in shares of Amgen by 12.1% in the first quarter. Badgley Phelps & Bell Inc. now owns 28,150 shares of the medical research company’s stock worth $4,221,000 after buying an additional 3,048 shares in the last quarter. Finally, Tiemann Investment Advisors LLC purchased a new position in shares of Amgen during the first quarter worth about $226,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded up 0.25% during trading on Thursday, hitting $164.29. The stock had a trading volume of 2,369,996 shares. The stock has a market cap of $122.95 billion, a price-to-earnings ratio of 16.81 and a beta of 0.94. The stock has a 50 day moving average price of $170.01 and a 200-day moving average price of $162.16. Amgen Inc. has a 12 month low of $139.02 and a 12 month high of $176.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same quarter last year, the business posted $2.57 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $11.35 EPS for the current year.

A number of equities research analysts have recently commented on AMGN shares. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $185.76 target price on the stock. in a research note on Tuesday, October 4th. Jefferies Group reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, September 28th. Citigroup Inc. decreased their price objective on Amgen from $175.00 to $172.00 and set a “neutral” rating for the company in a report on Wednesday, September 28th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a report on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and issued a $206.00 price objective (up previously from $204.00) on shares of Amgen in a report on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $184.94.

In other Amgen news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.